Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cea.14436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and Healthcare Cost Characteristics of Severe Asthma Patients with Long-Term Control on Omalizumab: A Comparative Analysis with Patients Who Switched to Other Biologics.
J Asthma Allergy
September 2025
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University Kyoto, Kyoto, Japan.
Background And Purpose: Biologics are crucial for severe asthma treatment, but their high costs pose challenges. Omalizumab (OML) is dosed on the basis of patient-specific factors. The purpose of this study is to clarify the clinical characteristics of severe asthmatics who maintain long-term control on omalizumab including healthcare cost considerations.
View Article and Find Full Text PDFThe Role of Biologic Therapy Switching to Optimize the Treatment of Severe Pediatric Asthma: Tezepelumab Is a New Therapeutic Alternative for Adolescents.
Children (Basel)
August 2025
Pediatric Service, University Hospital of Navarra (HUN), 31006 Pamplona, Spain.
Background/objectives: The emergence of biologic therapies has transformed the management of severe asthma, offering targeted treatments that improve symptom control and reduce exacerbations. However, taking a biologic solely based on the initial response may not be optimal. Clinicians must regularly reassess the suitability of the selected biologic, considering evolving patient characteristics and the growing availability of treatment options.
View Article and Find Full Text PDFEffectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab.
World Allergy Organ J
August 2025
Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear. This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose Urticaria Control Test (UCT) scores remained <12 after receiving at least 4 doses of omalizumab. Patients were transitioned to dupilumab after inadequate response to omalizumab.
View Article and Find Full Text PDFClinical Outcomes of Switching from Original Omalizumab to an Intended Copy Biosimilar in Chronic Urticaria: A Case Series Highlighting Global Regulatory Discrepancies.
Clin Exp Dermatol
August 2025
Department of Dermatology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India.
Evaluating Safety and Effectiveness of Switching Biologics in Managing Severe Asthma Patients.
J Asthma Allergy
August 2025
King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Background: The Saudi Initiative for Asthma (SINA) defines severe asthma as asthma that is uncontrolled at SINA step 4 despite optimized management. Choosing the biologic agent that is most appropriate for each patient can be difficult for clinicians. Thus, switching to another biologic agent due to no or suboptimal response is a common practice among asthma specialists.
View Article and Find Full Text PDF